Working on the Front Lines During the Early Days of the Pandemic Helped Her Commit to a Career in Clinical Research

Nicole Simons, MA, right, with Katherine Keller, Clinical Research Coordinator

When the first of several waves of COVID-19 cases hit New York City, Nicole Simons, MA, had just landed her first big job out of school as a research coordinator at the Icahn School of Medicine at Mount Sinai. In a matter of days, her dream job was eliminated, along with the jobs of several colleagues.

Then came the call from Human Resources: Could she take on a front-line job that would expose her to this unknown virus and clinics filled with COVID-19 patients? Her answer was a resounding yes.

In a moment of instant serendipity, she was reassigned to work for Alexander Charney, MD, PhD, a noted researcher in the field of schizophrenia, a disease that had first captured her attention in college.

Working closely with clinicians on the front lines during the pandemic would turn out to be a lifechanging experience. She visited hospital wards to collect samples, helped out staff when she could, and even served as a second author of a paper in Nature Medicine that described the team’s work. Now she is the Program Manager of the Jeff and Lisa Blau Adolescent Consultation Center for Resilience and Treatment and is a PhD student in the Clinical Research Program at the Icahn School of Medicine, with plans to continue research into the genetics of schizophrenia. “Working with clinical colleagues on the frontlines really got me thinking about how to narrow the gap between research and clinical care. I plan to use the lessons I’ve learned to keep building research programs that move us closer to becoming a true learning health care system.”

It’s a long way from those early days of the pandemic in 2020. Dr. Charney, Associate Professor, Psychiatry, and Genetics and Genomic Sciences, had been asked by hospital leadership to rapidly build up a COVID-19 Biobank that would collect hundreds of blood samples from patients hospitalized with COIVD-19. It would ultimately serve as a backbone for ongoing research into the virus and the human immune response.

Nicole Simons, MA

Dr. Charney’s team consisted of 100 volunteers who, like Ms. Simons, had seen their research projects paused but were given a chance to come help. The team quickly designed a sample-collection protocol, and once this was in place, the cadre of volunteers organized itself into six teams, with Ms. Simons assigned to the “Running Team.” This team was responsible for transporting collection kits to every location within the hospital, and then bringing those kits back.

What might sound like a simple and straightforward assignment involved a major hurdle. How to gain access to clinics where new hospital rules would not even allow families to enter, even when patients were seriously ill?  Ms. Simons would have to find a way in.

“Entering those clinics was like entering a fog of war environment. The strain on the nurses and doctors was palpable; we needed to visit their clinics without creating additional work for them” she says. They had to figure out a way to make easy for them to know if they should allow the researchers on the floor.

“I came up with this idea of making our research team stand apart so we’d be instantly recognizable.” Her solution: hot pink everything. “We wanted to stand out, so we wore hot pink scrubs, gloves, hairnets. Even our labels were pink,” she says. She and her teammates quickly developed a rapport with the nurses managing the floors they’d visit at all hours of the day and night.

“I felt like we were on the outside looking in, that we were somehow protected bystanders while they provided round-the-clock, unconditional care for their patients. To say thank you and support them, we brought them candy and other treats,” she says. They heard that nurses working in the tents constructed in Central Park needed clean, dry socks, so they asked for sock donations, and the response was instantaneous.

Lending help to the clinicians working in the hardest of circumstances also perpetuated for her a sense of shared purpose with staff and faculty at Mount Sinai. Among the volunteers at the Biobank, she found strength.

During the pandemic, Nicole Simons, MA, left, and a team collected hundreds of blood samples from patients hospitalized with COIVD-19, working with MIriam Merad, MD, PhD, center, Dean for Translational Research and Therapeutic Innovation, and Alexander Charney, MD, PhD,

“We all shared this common goal to collect those samples, no matter the hurdles.  When the hours were long, and the days were hard, we had this shared humanity that pulled us through,” she says.

When the team reached its goal of 500 samples, they pushed on, ultimately sampling more than 700 participants in 49 days, amounting to more than 10,000 vacutainers portioned into 50,000 smaller samples. A high level of organization was critical to success.

“But strong morale, in the darkest of times, was what really got us through those long days,” she says.  “At such a difficult time, it felt like a huge stroke of luck to be working for Dr. Charney, a psychiatrist, leading the Biobank team. His commitment to resilience and mental health was non-stop. He created a safety net for us, with regular weekly check-ins and the option for one-on-one counseling with him any time.”

In July 2020, she served as second author of a paper published in Nature Medicine describing the Biobank’s unique 49- day deep dive to uncover the pathogenicity of the virus. The authors would describe their journey as “not necessarily a model to follow, but rather a live-and-learn memoir of our actions and mistakes under uniquely strenuous circumstances.”

“The team was working intensely in a very high stress, high stakes environment, without much preparation for what we would all come to realize was a once in a lifetime experience,” says Dr. Charney, now Director of The Charles Bronfman Institute for Personalized Medicine and Vice Chair of the Windreich Department of AI and Human Health. “Their mental health was front and center for me. What pulled them through, I believe, was their strong purpose and being part of the group that didn’t have to stay home.”

How Mount Sinai Enabled One Data Scientist to Thrive in the Master of Biomedical Data Science and AI Program

“AI has infiltrated so many different aspects of everyone’s lives over the past few years, but seeing firsthand how it’s been able to make strides in virtually every field of science has been inspiring,” says Neeloy Bose.

Neeloy Bose, a first-year student in the Master of Biomedical Data Science and AI program at the Icahn School of Medicine at Mount Sinai, was already working in a laboratory and understood the importance of “Big Data.” But he concluded that in order to reach his goals, he had to learn more about how to process these large data sets himself, and how that can help researchers like him make discoveries that can improve health and help people.

In a Q&A, he describes how he decided to study at the Icahn School of Medicine and how that has helped him understand the value of studying data science.

Why did you decide to study at the Icahn School of Medicine at Mount Sinai?

The Icahn School of Medicine at Mount Sinai gives me the opportunity to access the resources of a world-renowned medical and academic institution while offering me the flexibility to continue my research externally.  The program specifically offered me the flexibility to continue my master’s studies in a hybrid setting while I am also working at the New York Stem Cell Foundation, a non-profit research institute based in Manhattan. It’s an exciting time to work with these institutions while being able to see what I’m studying brought to life through real world applications in the field.

What attracted you to study Biomedical Data Science and AI? What inspires you?

Working at a high-throughput lab that harnesses the power of automated liquid handling robots, I’ve come to appreciate the process of casually creating terabytes of data. This has only made me more appreciative of the extractive and generative power of data science, especially using AI and machine learning tools. Being able to create “Big Data” as a biologist means that you need someone to be able to work with a humanly incomprehensible amount of information, and what could be better than learning how to do it yourself?

How do you think AI is going to impact Data Science moving forward?

AI has infiltrated so many different aspects of everyone’s lives over the past few years, but seeing firsthand how it’s been able to make strides in virtually every field of science has been inspiring. From high-content image analysis to looking for signatures of rare diseases to even creating tools to assist health care outcomes, the intersection of AI and science seems brighter than ever, and that can only increase the speed at which we make progress towards the greater good.

What are some of your achievements so far as a master’s student?

I’d say being a master’s student is an achievement enough at times, but being able to learn the cutting edge of new technologies and taking that knowledge to be able to apply it to real-world research is fascinating. It almost feels surreal at points to know that you’re always working to advance the future of the field.

What are your plans after you have completed your degree?

I hope to transition from more wet lab facing roles to better integrate computation into my research. With what I’ve learned and will continue to learn through the program, I hope to keep pushing forward what I’ve learned and thought to be the boundaries of what science is capable of. Being able to see my work improving the real-world prospects of patients and health care systems using this ever-evolving technology would be one of my greatest dreams that I think I’ll always be in pursuit of.

How Mount Sinai Equipped Vibhor Mahajan, PhD, With the Skills to Bridge Clinical Research, Public Health, and Entrepreneurship

“The combination of research acumen and entrepreneurial thinking that I cultivated through my experiences has empowered me to drive meaningful change in both academia and industry,” says Vibhor Mahajan, PhD.

Vibhor Mahajan, PhD, earned his PhD in Clinical Research in January 2025 from the Icahn School of Medicine at Mount Sinai. Prior to that, he completed a Master of Public Health (MPH) in Healthcare Management. He now works as a Program Manager of Education and Entrepreneurship/Innovation with Mount Sinai Innovation Partners.

In a Q&A, he discusses what brought him to Mount Sinai for both degrees, why he selected this area of study, and how he expects this training to advance his career.

What brought you to Mount Sinai as a master’s student?

My decision to join Mount Sinai was driven by its reputation for cutting-edge research and its dynamic environment at the intersection of health care, technology, and innovation. Coming from an engineering background, I had already transitioned into health care through my work in quality improvement at Santa Clara Valley Medical Center in California, where I saw the potential for data-driven strategies to enhance patient care. Mount Sinai stood out not only for its focus on public health but also for its commitment to translating research into actionable health care solutions. The opportunity to learn from experts actively shaping health care policy and practice made it the ideal place to advance my knowledge and skills.

What were some of your achievements as a master’s student?

During my MPH, I had the chance to work on several impactful projects. One notable achievement was my master’s capstone project, which I worked on under the mentorship of Kritina Monti, PhD, LCSW, and Alexander Preker, MD, PhD. This project involved developing a machine learning-based application aimed at providing personalized care pathways for individuals with substance use disorders. It required analyzing complex datasets to identify behavioral patterns and ultimately conceptualizing an algorithm to improve treatment linkages. Additionally, I conducted a comprehensive analysis of emergency department utilization patterns related to behavioral health, which revealed opportunities for cost savings and better care delivery.

These efforts were recognized with several prestigious awards, which further reinforced my passion for using data-driven approaches to solve complex health care challenges and improve patient outcomes. During my MPH, I also had the opportunity to present my work at the American Public Health Association’s Annual Conference, with a travel grant from the MPH Program. My time as a master’s student was defined by combining technical expertise with public health principles to address real-world challenges in health care. These experiences not only shaped my academic and professional journey but also deepened my commitment to leveraging data and innovation to address pressing healthcare challenges

Why did you choose the PhD in Clinical Research program?

The PhD in Clinical Research at Mount Sinai attracted me because it offered a unique blend of scientific rigor and practical application, which perfectly aligned with my goal of advancing health care innovation. Having already explored process optimization and data-driven decision-making in clinical settings, I wanted to dive deeper into the intricacies of clinical trials and health systems. The program’s focus on developing new methodologies to improve clinical research infrastructure resonated with my passion for enhancing operational efficiency in health care.

What truly set the program apart for me was the opportunity to deepen my clinical research skills and  develop an entrepreneurial mindset through various opportunities offered at Mount Sinai. Through opportunities like the Targeted Healthcare Innovation Fellowship (THRIVE) by Mount Sinai Biodesign, and the Fellows Program by Mount Sinai Innovation Partners, I was able to hone my skills in translating research into practical, market-driven solutions, complementing my academic experience. I give huge credit to my mentors in the areas of entrepreneurship and biomedical ventures, especially Brian Nickerson, PhD, JD (who was also my PhD advisor) and Dov Shamir PhD. Through their guidance, I realized how important it is to have entrepreneurial thinking to bring solutions from bench to bedside and how practicality can improve overall health and quality of life.

As part of my dissertation, I worked closely with the Cardiothoracic Surgical Trials Network, developing a framework to evaluate the performance of clinical trial networks. This experience allowed me to combine both clinical research and entrepreneurial thinking, ensuring that the clinical trials I evaluated were not only scientifically sound but also strategically aligned with broader healthcare goals. The combination of research and entrepreneurial skills I gained throughout the PhD program has equipped me with a comprehensive skill set to drive innovation in both clinical research and health care entrepreneurship.

How did your public health experience help with completing your PhD in Clinical Research?

My public health training provided a crucial lens through which I approached clinical research. In the MPH program, I learned to evaluate health care interventions not only for their clinical efficacy but also for their economic and societal impact. This perspective allowed me to design a holistic evaluation framework for clinical trial networks during my PhD, integrating clinical, economic, and operational metrics to assess performance. Additionally, my experience in health data analysis during the MPH program helped me leverage large datasets to uncover insights about trial efficiency, patient recruitment, and resource allocation. The interdisciplinary nature of public health empowered me to think beyond the lab, considering broader policy implications and the real-world scalability of clinical research innovations.

How are you using your Mount Sinai degrees to advance your career?

My academic journey at Mount Sinai has equipped me with a versatile skill set that bridges clinical research, public health, and entrepreneurship. Today, as Program Manager of Education and Entrepreneurship/Innovation with Mount Sinai Innovation Partners, I help researchers and clinicians navigate the complex process of translating their innovations into viable health care solutions. The combination of research acumen and entrepreneurial thinking that I cultivated through my experiences has empowered me to drive meaningful change in both academia and industry, working to improve health care delivery and patient outcomes on multiple fronts.

How Mount Sinai Unlocked a Student’s Passion for Biomedical Research

“I decided to pursue a PhD in Biomedical Sciences in hopes that I could gain…independence as a researcher, and make contributions to bettering human health,” says Henry Weith.

As he embarked on a career after graduating college, Henry Weith did not initially think about continuing his education beyond a bachelor’s degree. Instead, he focused on finding the right job in industry.

Now a third-year student in the PhD in Biomedical Sciences program at the Icahn School of Medicine at Mount Sinai in the Development, Regeneration, and Stem Cells (DRS) Multidisciplinary Training Area, he works in the laboratory of Alison May, PhD, studying exocrine gland development and preparing for a career that will allow him to address larger scientific areas of inquiry that could eventually improve human health.

“I decided to pursue a PhD in Biomedical Sciences in hopes that I could gain…independence as a researcher, and make contributions to bettering human health,” he says. “Once starting my PhD at Mount Sinai, I found an additional passion for biomedical research that had been hidden under years of tedious, yet essential, courses in cell and molecular biology.”

In this Q&A, he discusses his journey towards a career in biomedical research, and how Mount Sinai is helping him achieve his goals. He explains how learning about what he calls the “innate beauty of developmental biology” demonstrated that unique patterns in nature, something as simple as the scales of a butterfly wing, could be important to understanding the workings of the human body, even something like the human salivary gland. And how working out in the gym is a bit like scientific research in the way hard work is eventually rewarded.

Why continue your education with a PhD in Biomedical Sciences?

Growing up I had never considered continuing my education beyond a bachelor’s degree. Career planning during my undergraduate education was mainly focused on finding a job, which in my major of bioengineering meant an industry position at a biotech company. In subsequent biotech research internships, I recognized that many of the scientists independently directing projects had attained PhDs, which not only gave them more responsibility, but expertise in complex subjects that allowed them to address expansive biological questions that contributed to essential therapies to treat diseases.

What made you interested in the Development, Regeneration, and Stem Cells training area?

One of my first academic research experiences attempted to understand the genomics regulating wing patterning in tropical butterfly species of Central and South America. This experience taught me the innate beauty of developmental biology, not just in the colorful and diverse structures it generates, but also the intricate molecular dynamics that regulate it. Patterning in biology is not just relevant in determining the scales of a butterfly wing but is also crucial to define the body axis of a fly, organize the limb buds of a developing mouse paw, or regulate the branching of a human salivary gland—all of which I believe to be equally beautiful and complex.

Can you give an example in the work in your training area?

In the DRS training area, I’m able to ask fundamental questions and utilize approaches including live cell fluorescent imaging, high throughput transcriptional sequencing, and transgenic animal models to understand how cells are programmed, how they communicate with each other and their environment, and how they appropriately pattern to form healthy tissues. This understanding can then be used to develop regenerative therapies to restore damaged tissues and treat diseases. The faculty of DRS share and enhance this curiosity-driven research through engaging seminars with questions from audience members. In DRS, I’m surrounded by like-minded individuals passionate about teasing apart the basic principles of development and tissue homeostasis.

Why did you choose to study at Mount Sinai?

Mount Sinai offered rigorous research, a welcoming environment, and unbeatable location. I wasn’t certain what specific research I wanted to pursue for my thesis when applying to PhD programs. The number of laboratories at Mount Sinai is extensive and they cover many areas of biomedical science. I was certain I would easily find an interesting research home, which I did following four rotations which made it hard to pick just one. Not only were there lots of exciting and advanced research available, but also the researchers—the current PhD students, post docs, and faculty—were emblematic of an environment that valued collaboration, passion for science, and fulfilling lives outside of research. Everyone I talked to during interviews had a passion outside of research including art, food, athletics, and more. Not only did I feel I’d have adequate work-life balance at Mount Sinai, but its location in New York City meant I could truly make the most of my time outside of the lab, whether it’s running in the park, seeing movies weekly at local theatres, or going out to concerts on the weekend.

What activities outside the classroom have contributed to your success?

Exercise, running or weightlifting outside of lab, has been crucial to maintaining adequate mental health—which I find to be incredibly important for success in research. I know exercise can be very cliché, but what I find most useful about exercise is how hard work is translated to progress in a very straight-forward manner. Biomedical research is full of ups and downs, and sometimes, no matter how hard you try, experiments just don’t work. With exercise, if I run one mile today, tomorrow I’ll likely be able to run 1.25 miles, and if I lift 50 pounds today, tomorrow I may be able to lift 55 pounds. This progress, achieved outside of lab, helps to maintain my self-confidence and assurance that I’m moving forward, even if it doesn’t always feel like my research is.

 What are your plans after you complete your PhD?

My current interests align with pursuing a faculty position at an academic research institution where I can split my time between running a lab and teaching. In academia, scientists can have control over their research and the questions they are driven to explore. I value being able to explore scientific phenomena based on curiosity and current health needs outside of the pressure of making profit. Additionally, I’ve enjoyed the experience of mentoring student trainees in lab. After working as a teaching assistant for the Development and Regeneration section of the first-year Biomedical Sciences core course, I want to continue educating budding scientists.

Any thoughts about future research projects?

I’ve enjoyed conducting basic biology research on epithelial development but would love to expand to different organ systems and cell types as well as other model organisms. I plan on pursuing a post-doctoral fellowship immediately following my PhD in hopes of gaining more independence as a research scientist and expanding my expertise to a wider breadth of research topics.

Racing to Stop a Pandemic: The Critical Role of Clinical Trials

A group photo of the COVID-19 Clinical Trial Unit, part of the Mount Sinai Infectious Diseases Clinical and Translational Research Center.

When the COVID-19 pandemic ramped up in New York City in March 2020, the disease was so novel there was no approved treatment for it.

“We saw people come to the hospital with COVID-19, and without specialized treatments, many died,” said Sean Liu, MD, PhD, Associate Professor of Medicine (Infectious Diseases) at the Icahn School of Medicine at Mount Sinai. “I remember feeling helpless, and helplessness is probably the worst feeling that a doctor could experience, because people come to you for help but there is only so much you can do or give.”

With a dire need to discover treatments for patients, the Mount Sinai Infectious Diseases Clinical and Translational Research Center (CTRC) formed the COVID-19 Clinical Trial Unit (COVID CTU) in June 2020 to find ways to stop the disease.

“We already had experts beginning the effort, and with the support of Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine, and under the leadership of Judith Aberg, MD, Director of the CTRC, we were able to form the COVID CTU and go all in to stop COVID-19,” said Dr. Liu, who was tapped as Medical Director of the research unit.

The COVID CTU conducted interventional studies in all aspects of tackling COVID-19, including several drugs that were ultimately approved by the U.S. Food and Drug Administration (FDA). These include Regeneron’s monoclonal antibody therapies, Gilead Sciences’ remdesivir, and two COVID-19 vaccines.

Judith Aberg, MD, Director of the Mount Sinai Infectious Diseases Clinical and Translational Research Center (left) and Sean Liu, MD, PhD, Medical Director of the COVID-19 Clinical Trials Unit (right).

In this Q&A, Dr. Liu and Dr. Aberg share their experience of how the COVID CTU worked tirelessly throughout the pandemic, and where it is headed in the future.

How did the COVID CTU come to be formed?

Dr. Aberg: We were able to build upon the infrastructure that was created for HIV clinical trials, along with the support of many, to immediately start two different drug trials for COVID-19. One drug aimed at the SARS-CoV-2 virus and the other was a potent anti-inflammatory. And I must say, our prompt efforts paid off. We were able to give remdesivir, an antiviral drug, via a compassionate use application on March 9—within two days of the admission of our first patient at Mount Sinai West.

Dr. Liu: When the pandemic first hit, I was working as a hospitalist—someone who cares for admitted patients—at Mount Sinai Queens, and Dr. Aberg asked me to help with clinical trials at The Mount Sinai Hospital.

As pharmaceutical companies started developing more candidates for COVID-19 treatment, the team working on the initial studies started taking on more studies, supported by the CTRC, the Infectious Diseases Division, and the Medicine Clinical Trials Office at the Icahn School of Medicine. When we realized we sorely needed to expand and formalize a team for COVID-19-related trials, Dean Charney provided seed funding, and during the summer of 2020, we were able to hire more staff needed to run the trials.

How big was the COVID CTU then, and how has it grown since?

Dr. Liu: It started with 11 people, including six from the CTRC. By 2021, we had 25 staff.

What was it like fielding a clinical trials team during the pandemic?

Dr. Liu: Dr. Aberg already had a research unit working with HIV before the pandemic, and we pooled together a staff of clinical researchers, project managers, research nurses, coordinators, and regulatory staff. It was incredible seeing so many people come together quickly to tackle one of the biggest challenges we’ve faced in health care.

In addition to assessing the effectiveness of industry-developed treatments, the unit became a translational springboard where basic science researchers could come to us with their ideas, and we could help apply them in a phase 1 study, creating a bridge between preclinical and in-human studies.

What were some of the COVID-19 trials done at Mount Sinai?

Drs. Aberg and Liu recall some of the studies done by the COVID CTU:

  • Remdesivir: The antiviral drug is currently approved by the FDA to treat patients hospitalized for COVID-19. We initially opened trials for this drug via an emergency investigational new drug application at seven hospitals. In less than a month, we opened the Gilead-sponsored studies at four hospitals.
  • Monoclonal antibodies (mAbs): We were involved in Regeneron’s mAb studies in many different settings. These included an outpatient treatment study, an outpatient post-exposure prophylaxis study, and a pre-exposure prophylaxis study. One of Regeneron’s mAb that we did a study on was sarilumab, a potent IL-6 inhibitor. While this study did not demonstrate the robust findings of another IL-6 inhibitor we had worked on, Roche’s tocilizumab, it was the first study that paved the way for potent immune-modulating therapies to treat COVID-19 as we do currently.
  • mRNA vaccine: We were heavily engaged in the Pfizer/BioNTech COVID-19 vaccine trial, enrolling hundreds of participants from diverse backgrounds. Mount Sinai was recognized for enrolling the 40,000th participant in the initial phase 3 trial.
  • NDV-HXP-S: Mount Sinai developed its own COVID-19 vaccine, which can be delivered via injection or the nose. The technology was developed by our Microbiology Department, and the COVID CTU helped run the phase 1 trial. With our data, the vaccine went on to be developed further in other countries and has gone on to be approved as booster shots in Mexico and Thailand.
  • Hyperimmune immunoglobulin: This was a blood product-derived treatment using extracted antibodies from a pool of convalescent plasma donors who had recovered from COVID-19. With hyperimmune immunoglobulin, the patient is receiving a known purified amount of antibody from the donor. Studies are ongoing to identify who would benefit the most as well as timing in relation to onset of symptoms.

The COVID Clinical Trials Unit team received a letter of recognition for enrolling 280 participants—as well as the 40,000th participant—in the Pfizer/BioNTech COVID-19 vaccine trial.

What were some lessons learned on running clinical trials to address the pandemic?

Dr. Liu: There were so many studies to undertake, but we had to learn to focus. A part of it was trial and error, but as we gained experience, we became better at identifying what studies were likely to yield promising results. Some clinical trials might sound great on paper, but given limited resources, we had to weigh what factors went into them—such as enrollment opportunity or viral targets—and choose our trials accordingly or make adjustments.

Dr. Aberg: Decisive action can help change the trajectory of a pandemic. When Regeneron finalized its protocol for sarilumab trials, within seven days we opened a randomized, placebo-controlled trial of the drug. Its interim results, along with our remdesivir clinical trials and observational use of tocilizumab, helped advise us of the narrow window where these types of drugs may be effective to prevent patients from developing respiratory failure, requiring them to go on a ventilator, and even death.

What’s next for the COVID CTU?

Dr. Aberg: The COVID CTU no longer needed to be distinct from the CTRC. However, we are still involved in COVID-19 studies. One such trial is RECOVER-VITAL, a National Institutes of Health (NIH)-funded study to explore whether Pfizer’s Paxlovid™ treatment can be used to treat the chronic disease state commonly referred to as long COVID.

We are also in the NIH-funded Strategies and Treatments for Respiratory Infections and Viral Emergencies (STRIVE) consortium. A COVID-19 study we are involved in as part of the network is STRIVE-1, exploring whether the antiviral medication ensitrelvir can reduce symptoms and duration of hospitalization in persons with moderate to severe COVID-19. Another STRIVE COVID-19 study is exploring the additional use of immunomodulating agents for hospitalized patients.

Beyond COVID-19, we completed enrollment for a few other studies, including an mRNA shingles vaccine study by Pfizer and an exciting novel dual-affinity retargeting molecule for HIV. There are other studies we anticipate opening in 2025, including a C. difficile vaccine, as well as several HIV prevention and treatment studies.

Dr. Liu: We will never forget how the COVID-19 pandemic changed our lives. Thanks to tested vaccines and treatments, we are able to return to a normal life of packed movie theaters and lecture halls. Some of our team of skilled and knowledgeable research staff are being transferred to other areas where groundbreaking research is occurring throughout the Mount Sinai Health System. We are forever grateful for the contributions of the COVID CTU in reducing the morbidity and mortality from the COVID-19 pandemic.

A Mount Sinai Medical Student, Whose Work Helped a Young Boy Recover From Nearly Drowning, Reflects on Her Research and Aspirations

From left: Farid Khan, MBBS, co-chair of the Fellows in Training Program of the New York Chapter of the American College of Cardiology; Helen Gordan; and Samuel Kim, MD, the chapter’s program chair

Helen Gordan, a second-year medical student at the Icahn School of Medicine at Mount Sinai, recently won best clinical case abstract at the New York Chapter of the American College of Cardiology Fellows in Training competition.

Her abstract titled “Unraveling a Genetic Diagnosis After a Near Drowning Incident” describes the diagnostic odyssey of a 9-year-old boy who was cared for at Mount Sinai Kravis Children’s Hospital after he was resuscitated from near-drowning in a swimming pool.

Careful sleuthing ultimately elicited a novel cardiac genetic cause. The patient made a full recovery and is being treated successfully, and the genetic discovery will permit others to benefit in the future.

Ms. Gordan’s award is all the more impressive for having won it as a second-year medical student, competing against much more senior trainees in internal medicine and cardiology fellowship training.  Ms. Gordan presented the work in an oral presentation in December.

In a Q&A, Ms Gordan discusses why she chose the Icahn School of Medicine at Mount Sinai, what has drawn her to explore pediatric cardiology as a potential career choice, and her research interests.

What inspired you to explore pediatric cardiology as a medical student?

From the beginning of medical school, I was drawn to specialties that offer meaningful long-term patient relationships and combine medical management with precise interventions. Pediatric cardiology fulfills both these criteria and more. Since every heart is unique, cardiologists must rely on fundamental physiologic principles to tailor treatments to each case. The opportunity for early intervention, especially in congenital heart defects, has an immeasurable impact on long-term outcomes, enabling children to thrive and lead full lives. It opens the door to the kind of long-term relationships with patients and families that I desire in my career.

What are your research interests?

My research interests lie at the intersection of engineering and clinical care. My undergraduate degree is in electrical engineering, so I am particularly interested in how technology can be harnessed to both enhance therapeutic outcomes and improve access to care for underserved populations. For example, asynchronous online care platforms—which allow physicians to assess patient concerns and provide treatment through messaging, patient portals, or online questionnaires— offer unique opportunities to bridge gaps in accessibility, especially for resource-limited settings. Understanding how these models can integrate with chronic disease management, including heart disease, is a growing area of interest.

What does winning this abstract award mean to you and how will it help propel your studies?

I was incredibly excited and honored to win this case competition. It has encouraged me to continue to explore challenging questions and raise questions about frameworks for diagnoses. It has allowed me to receive feedback from experts that have both refined my skills and broadened my perspective. Most importantly, it has underscored the importance of great mentorship and collaboration. I am incredibly grateful for the support I received from Dr. Barry Love and Dr. Amy Kontorovich while working on this case.

Why did you choose the Icahn School of Medicine school and how has the medical school experience been so far?

The Icahn School of Medicine stood out to me because of its emphasis on fostering diverse academic backgrounds. Coming from an engineering discipline, I was eager to join a medical institution that values multidisciplinary approaches to problem-solving and allows students to incorporate their own interests into their clinical training. The culture of innovation and research has completely exceeded these expectations. I have been able to learn about entrepreneurship in medicine through Sinai BioDesign’s THRIVE program, explore access-to-care barriers through a summer global health research program, and explore different specialties with the support of amazing faculty. My experience has been exceptional, largely due to the supportive mentorship I’ve received from Dr. Love, Dr. Gault, and many others.

What do you hope your impact will be on patients, field, and practice?

First and foremost, I hope to be an exceptional clinician. I would like to provide the expertise and empathy patients need when facing scary and vulnerable moments. I also aspire to combine innovation with equitable care to make an impact. I hope to provide solutions that enhance quality of life while ensuring accessibility to care, regardless of socioeconomic or geographic barriers. Ultimately, I want my career to serve as a bridge between disciplines and help to drive advancements that improve both individual patient experiences and systemic health care delivery.

Pin It on Pinterest